PRNewsWire · October 25, 2026

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine

Get the app for more

Explore stock news, insights and company research.